Page last updated: 2024-11-04

sibutramine and Froehlich's Syndrome

sibutramine has been researched along with Froehlich's Syndrome in 1 studies

sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride

Research Excerpts

ExcerptRelevanceReference
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial."9.12Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007)
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial."5.12Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Danielsson, P1
Janson, A1
Norgren, S1
Marcus, C1

Trials

1 trial available for sibutramine and Froehlich's Syndrome

ArticleYear
Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:11

    Topics: Absorptiometry, Photon; Adolescent; Adult; Antidepressive Agents; Body Weight; Child; Child, Prescho

2007